Aug. 3, 2017—Researchers in the Vanderbilt Institute for Global Health are testing whether a unique “couples-centered” intervention developed in the southern African nation of Mozambique can reduce mother-to-child transmission of HIV.
Apr. 27, 2017—The first large study to report that HIV-infected people have a significantly higher risk of heart failure in the antiretroviral therapy era has been published in JAMA Cardiology.
Apr. 14, 2016—This month an international HIV prevention trial was launched that is testing the infection-preventing prowess of a monoclonal antibody called VRCO1.
Apr. 7, 2016—It’s been known for some time that the immune system can produce antibodies capable of “neutralizing” HIV, and stopping the AIDS-causing virus dead in its tracks.
Mar. 17, 2016—An international research team led by scientists from Vanderbilt University Medical Center has identified a genetic variant that protects people with HIV from developing active tuberculosis. The variant is near the gene encoding the infection-fighting cytokine IL-12.
Oct. 8, 2015—The first study to suggest that major depressive disorder (MDD) is an independent risk factor for heart failure in HIV-positive adults has been published in Circulation.
Aug. 20, 2015—The Vanderbilt Institute for Global Health (VIGH) has received two new grants from the Fogarty International Center of the National Institutes of Health (NIH) to build HIV-focused research capacity with key partners in Zambia, Mozambique and Brazil.
Jun. 25, 2015—Vanderbilt University has received a five-year grant from the National Institutes of Health (NIH) to establish the Tennessee Center for AIDS Research with Meharry Medical College and the Tennessee Department of Health.
May. 21, 2015—With the help of a computer program called “Rosetta,” researchers at Vanderbilt University have “redesigned” an antibody that has increased potency and can neutralize more strains of the AIDS-causing human immunodeficiency virus (HIV) than can any known natural antibody.